Joshua Michael Bauml

基本信息

Career Trajectory

Bio

Dr. Joshua Bauml is a medical oncologist in Philadelphia, Pennsylvania and is affiliated with multiple hospitals in the area, including Hospitals of the University of Pennsylvania-Penn Presbyterian and Philadelphia Veterans Affairs Medical Center.

Research Interests

Papers共 238 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Amivantamab Plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Byoung C. Cho,Shun Lu,Enriqueta Felip,Alexander I. Spira,Nicolas Girard,Jong-Seok Lee,Se-Hoon Lee,Yurii Ostapenko,Pongwut Danchaivijitr,Baogang Liu,Adlinda Alip,Ernesto Korbenfeld,Josiane Mourao Dias,Benjamin Besse,Ki-Hyeong Lee,Hailin Xiong,Soon-Hin How,Ying Cheng,Gee-Chen Chang,Hiroshige Yoshioka,James C. -H. Yang,Michael Thomas,Danny Nguyen,Sai-Hong I. Ou, Sanjay Mukhedkar,Kumar Prabhash,Manolo D'Arcangelo,Jorge Alatorre-Alexander, Juan C. Vazquez Limon, Sara Alves,Daniil Stroyakovskiy, Marina Peregudova,Mehmet A. N. Sendur,Ozan Yazici,Raffaele Califano, Vanesa Gutierrez Calderon,Filippo de Marinis,Antonio Passaro,Sang-We Kim,Shirish M. Gadgeel,John Xie,Tao Sun,Melissa Martinez, Mariah Ennis, Elizabeth Fennema,Mahesh Daksh,Dawn Millington, Isabelle Leconte,Ryota Iwasawa,Patricia Lorenzini,Mahadi Baig, Sujay Shah,Joshua M. Bauml,S. Martin Shreeve, Seema Sethi,Roland E. Knoblauch,Hidetoshi Hayashi

The New England journal of medicineno. 6 (2025): 620-621

Cited21Views0WOSBibtex

Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study

G. Lopes,A. I. Spira,J. -Y. Han,J. -Y. Shih, C. Mascaux, U. Basu Roy,J. Zugazagoitia,Y. J. Kim,C. -H. Chiu, S. -W. Kim,E. Nadal,I. Gil-Bazo, S. Murphy,P. Mahadevia, B. G. Anderson,K. Xia, G. Wang,J. M. Bauml,M. Chioda, J. Simoes, L. Paz-Ares

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S104-S105

Cited0Views0Bibtex

Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study

JOURNAL OF CLINICAL ONCOLOGYno. 30 (2024)

Cited0Views0WOSBibtex

1269P Preventing Infusion-Related Reactions with Intravenous Amivantamab: Updated Results from SKIPPirr, a Phase II Study

L.G. Paz-Ares,A.I. Spira,J-Y. Han,J-Y. Shih, C. Mascaux, U. Basu Roy,J. Zugazagoitia, Y.J. Kim,C.H. Chiu,S-W. Kim,E. Nadal,I. Gil Bazo,P. Mahadevia, B. Anderson,K. Xia, G. Wang,J.M. Bauml,M. Chioda, J. Simões,G. Lopes

Annals of Oncology (2024): S812

Cited0Views0Bibtex

LBA55 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Versus Osimertinib in Patients with EGFR-mutant Advanced Non-Small Cell Lung Cancer: an Early Analysis from the Phase III MARIPOSA Study

B. Besse,S-H. Lee,S. Lu,D. Stroyakovskiy,O. Yazici,J.R. Rodriguez Cid, H. Hayashi,D. Nguyen,J.C-H. Yang,M. Gottfried, A.C. Gelatti,S. Owen,S-H.I. Ou, M. Ennis, S. Sethi,J.M. Bauml, J. Zhang,J.C. Curtin,B.C. Cho

Annals of Oncology (2024): S1245-S1246

Cited0Views0Bibtex

OA06.04 Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow Up

M.E. Marmarelis, D.J. Cantor,D. Mathew, T. McWilliams,J. Bauml,W.-T. Hwang, A. Singh,C. D'Avella, C. Davis, D. Ye, L. Sun,C. Ciunci,C. Aggarwal,R.B. Cohen, A. Minn, J. Wherry,C.J. Langer

Journal of Thoracic Oncologyno. 10 (2024): S20

Cited0Views0Bibtex

Amivantamab Plus Lazertinib Vs Osimertinib in Firstline EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

S. Gadgeel,B. C. Cho,S. Lu,E. Felip,H. Hayashi,A. I. Spira,B. Besse, M. Thomas,S. Owen,Y. J. Kim,S. -H. Lee,J. Mourao Dias,Y. -G. Lee, Y. Zhao, Y. Fang,N. Girard, Z. Liu,P. Sun, S. C. Sousa Oliveira, H. Shen,L. Paz-Ares, S. Matsumoto, H. Tanaka, A. R. Ahmad, T. Andabekov,P. Sunpaweravong, O. Ozyilkan,J. C. -H. Yang,M. Gottfried, O. Hernandez,M. Kimmich,D. Cortinovis, D. L. Kaen, L. V. Garcia Montes,S. Popat, T. Newsom-Davis,J. Xie,T. Sun,E. Fennema, M. Daksh, M. Ennis, S. Sethi,J. M. Bauml,D. Nguyen

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S10-S11

Cited0Views0Bibtex

Enhanced Vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

B. C. Cho,N. Girard, M. B. Sauder, J. Feldman, W. Li,F. Bozorgmehr,M. Mak, J. Smith, J. Simoes,P. Mahadevia, B. G. Anderson, T. Romero,K. Xia, G. Wang, S. Murphy,J. M. Bauml,A. I. Spira

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S347-S347

Cited0Views0Bibtex

Amivantamab Plus Chemotherapy with and Without Lazertinib in EGFR-mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study

A. Passaro,J. Wang, Y. Wang,S. -H. Lee,B. Melosky,J. -Y. Shih,K. Azuma,O. Juan-Vidal,M. Cobo,E. Felip,N. Girard,A. B. Cortot,R. Califano,F. Cappuzzo,S. Owen,S. Popat,J. -l. Tan, J. Salinas,P. Tomasini,R. D. Gentzler,W. N. William,K. L. Reckamp, T. Takahashi, S. Ganguly,D. M. Kowalski,A. Bearz,M. MacKean, P. Barala,A. B. Bourla, A. Girvin, J. Greger,D. Millington, M. Withelder,J. Xie,T. Sun, S. Shah,B. Diorio,R. E. Knoblauch,J. M. Bauml, R. G. Campelo,B. C. Cho

ANNALS OF ONCOLOGYno. 1 (2024)

Cited93Views0WOSBibtex

3MO Amivantamab Plus Chemotherapy Vs Chemotherapy in EGFR-mutant Advanced NSCLC after Progression on Osimertinib: A Post-Progression Analysis of MARIPOSA-2

R.D. Gentzler,A. Spira,B. Melosky,S. Owen, T. Burns,E. Massarelli, M. Nagasaka, B. Fang,R.E. Sanborn,O.G. Arrieta Rodriguez, C. Card,F. Cappuzzo,K. Xia, P-L. Chu, S. Shah,B. Diorio, A. Garvin,P. Mahadevia,J.M. Bauml,K. Reckamp

ESMO Open (2024): 102582

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Executive Medical Director

Papers共 238 篇Author StatisticsCo-AuthorSimilar Experts